Inovio presents clinical results of its dna medicines ino-5401 + ino-9012 in novel combination with pd-1 inhibitor libtayo® (cemiplimab) in the treatment of newly diagnosed glioblastoma multiforme at society for neuro-oncology 2020 annual meeting

Plymouth meeting, pa., nov. 20, 2020 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on rapidly bringing to market precisely designed dna medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's novel...
INO Ratings Summary
INO Quant Ranking